Alethia Young Biography and Net Worth

Ms. Young has over 20 years of experience in biopharmaceutical industry. Currently, Ms. Young is the chief financial officer at Bicycle Therapeutics. In this role, Ms. Young oversees the company’s finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy. She also serves on the board of directors for PTC Therapeutics and Pacira Biosciences.

Previously Ms. Young served as chief financial officer at Graphite Bio, senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering large cap and small-mid-cap biotechnology companies. Prior to joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions.

Ms. Young earned a B.A. in Economics and Spanish from Duke University. She currently serves on the board of directors for BUILD NYC.

What is Alethia Young's net worth?: The estimated net worth of Alethia Young is at least $319.19 thousand as of October 2nd, 2025. Young owns 44,704 shares of Bicycle Therapeutics stock worth more than $319,187 as of December 5th. This net worth evaluation does not reflect any other investments that Young may own. Additionally, Young receives a salary of $581,690.00 as CFO at Bicycle Therapeutics. Learn More about Alethia Young's net worth.
How old is Alethia Young?: Young is currently 45 years old. There are 6 older executives and no younger executives at Bicycle Therapeutics. The oldest executive at Bicycle Therapeutics is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director, who is 73 years old. Learn More on Alethia Young's age.
What is Alethia Young's salary?: As the CFO of Bicycle Therapeutics PLC Sponsored ADR, Young earns $581,690.00 per year. There are 4 executives that earn more than Young. The highest earning executive at Bicycle Therapeutics is Dr. Kevin Lee M.B.A., Ph.D., CEO & Executive Director, who commands a salary of $1,350,000.00 per year. Learn More on Alethia Young's salary.
How do I contact Alethia Young?: The corporate mailing address for Young and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Alethia Young's contact information.
Has Alethia Young been buying or selling shares of Bicycle Therapeutics?: Within the last three months, Alethia Young has sold $4,101.82 in shares of Bicycle Therapeutics stock. Most recently, Alethia Young sold 482 shares of the business's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $8.51, for a transaction totalling $4,101.82. Following the completion of the sale, the chief financial officer now directly owns 44,704 shares of the company's stock, valued at $380,431.04. Learn More on Alethia Young's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Santiago Arroyo (Insider), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), Pierre Legault (Director), Alistair Milnes (COO), Michael Skynner (CTO), Travis Thompson (CAO), and Alethia Young (CFO). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 49,366 shares worth more than $563,681.34. The most recent insider tranaction occured on October, 3rd when CEO Kevin Lee sold 3,231 shares worth more than $27,172.71. Insiders at Bicycle Therapeutics own 22.9% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 10/3/2025.

Alethia Young Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/2/2025	Sell	482	$8.51	$4,101.82	44,704
7/2/2025	Sell	204	$7.09	$1,446.36	45,186
4/2/2025	Sell	215	$8.02	$1,724.30	45,390
1/2/2025	Sell	1,395	$14.09	$19,655.55	45,605

Alethia Young Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $7.14

$6.96

$7.27

50 Day Range

MA: $7.48

$6.17

$8.87

2 Week Range

Now: $7.14

$6.03

$21.50

Volume

302,559 shs

Average Volume

327,116 shs

Market Capitalization

$495.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Alethia Young Biography and Net Worth

What is Alethia Young's net worth?

How old is Alethia Young?

What is Alethia Young's salary?

How do I contact Alethia Young?

Has Alethia Young been buying or selling shares of Bicycle Therapeutics?

Who are Bicycle Therapeutics' active insiders?

Are insiders buying or selling shares of Bicycle Therapeutics?